Application of pseudomonas aeruginosa vaccine in treating infection associated with burn or scald injury

Abstract

The present invention belongs to the field of microbiology, and particularly relates to an application of a Pseudomonas aeruginosa vaccine in prevention and treatment of burn and scald complicated with bacterial infection. The burn and scald of the present invention include burns and scalds, and degree of the scalds includes I degree, superficial II degree, deep II degree, or III degree scalds. Site of the scalds includes skin, mucosa or other tissues. The Pseudomonas aeruginosa vaccine of the present invention can effectively prevent and treat burn and scald complicated with Pseudomonas aeruginosa infection caused by multidrug-resistant Pseudomonas aeruginosa by activating the specific immune response of the body. The Pseudomonas aeruginosa vaccine of the present invention can reduce the bacterial load in the immunized subject through the established immunization procedures, thereby providing a technical solution that can effectively prevent burn and scald complicated with Pseudomonas aeruginosa infection, which avoids the technical problems caused by the use of antibiotics such as poor effectiveness, difficulty in curing and proneness to drug resistance in the prior art to a certain degree.

1 . Use of a  Pseudomonas aeruginosa  vaccine in manufacture of a medicament for prevention and treatment of bacterial infection in burn and scald, wherein the burn and scald are complicated with the bacterial infection and the bacterial infection is  Pseudomonas aeruginosa  infection; the  Pseudomonas aeruginosa  vaccine comprises inactivated  Pseudomonas aeruginosa  and/or  Pseudomonas aeruginosa  membrane vesicles; wherein the inactivated  Pseudomonas aeruginosa  is inactivated by irradiation, and the  Pseudomonas aeruginosa  membrane vesicles are isolated from the  Pseudomonas aeruginosa  inactivated by irradiation. 
     
     
         2 . The use according to  claim 1 , wherein the burn and scald include burns and scalds, and degree of the scalds includes I degree, superficial II degree, deep II degree, or III degree scalds. 
     
     
         3 . The use according to  claim 2 , wherein site of the scalds includes skin, mucosa or other tissues. 
     
     
         4 . (canceled) 
     
     
         5 . (canceled) 
     
     
         6 . (canceled) 
     
     
         7 . (canceled) 
     
     
         8 . The use according to  claim 1 , wherein site of the scalds includes skin, mucosa or other tissues. 
     
     
         9 . (canceled) 
     
     
         10 . The use according to  claim 1 , wherein immunization procedures of the  Pseudomonas aeruginosa  vaccine comprise: injection take places (i) 0, 3rd, and 7th days, and (ii) 0, 2nd and 4th weeks. 
     
     
         11 . (canceled) 
     
     
         12 . The use according to  claim 1 , wherein the  Pseudomonas aeruginosa  vaccine prevents  Pseudomonas aeruginosa  infection, and reduces bacterial load in skin scald complicated with bacterial infection. 
     
     
         13 . The use according to  claim 1 , wherein content of whole-cell  Pseudomonas aeruginosa  in the  Pseudomonas aeruginosa  vaccine comprises: 1×10 4 -1×10 10 /injection. 
     
     
         14 . The use according to  claim 13 , wherein the content of whole-cell  Pseudomonas aeruginosa  in the  Pseudomonas aeruginosa  vaccine comprises: 1×10 4 /injection, 1×10 5 /injection, 1×10 6 /injection, 1×10 7 /injection, 1×10 8 /injection, 1×10 9 /injection and 1×10 10 /injection. 
     
     
         15 . The use according to  claim 1 , wherein the  Pseudomonas aeruginosa  vaccine further contains an immunoadjuvant. 
     
     
         16 . The use according to  claim 15 , wherein the immunoadjuvant is aluminum hydroxide. 
     
     
         17 . The use according to  claim 1 , wherein administration site of the  Pseudomonas aeruginosa  vaccine is subcutaneous, muscle and/or mucosa. 
     
     
         18 . The use according to  claim 1 , wherein the medicament can also contain any pharmaceutically acceptable carrier and/or adjuvant. 
     
     
         19 . The use according to  claim 18 , wherein the carrier is a liposome.